TFRC and Alzheimer disease: To enable preclinical studies in AD transgenic mice, the anti-Abeta ScFv was fused to the carboxyl terminus of each heavy chain of the 8D3-derived TfRMAb, and this BSA retained high affinity binding to both the mouse TfR and Aβ1–40 [794].